2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
11
Thoracic
9
Gastrointestinal
5
CNS
2
Tumor-Agnostic
1
Other solid neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Conditions
Brain Neoplasms
2
Meningeal Neoplasms
1
Breast Neoplasms
1
Interventions
Temozolomide
623
Radiotherapy
411
Bevacizumab
257
Magnetic Resonance Spectroscopy
227
Cyclophosphamide
179
Radiosurgery
163
Carboplatin
160
Etoposide
132
Radiation
129
Vincristine
115
Irinotecan
115
Cisplatin
103
Filgrastim
100
Specimen Handling
90
Nivolumab
88
pembrolizumab
84
Surgical Procedures, Operative
83
Lomustine
82
Topotecan
73
Doxorubicin
61
Melphalan
59
Carmustine
57
Radiotherapy, Intensity-Modulated
56
sargramostim
53
Isotretinoin
53
Peripheral Blood Stem Cell Transplantation
52
Granulocyte Colony-Stimulating Factor
51
Chemotherapy, Adjuvant
51
Blood Specimen Collection
51
Erlotinib Hydrochloride
50
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
patritumab deruxtecan
×
CNS
×
Clear all
NCT05865990
2026-05-04
TUXEDO-3
MedSIR
Phase 2
Completed
63 enrolled
NCT05620914
2025-06-15
PARAMETer
Duke University
Phase 2
Withdrawn